Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

24 Nov 2021

Abstract excerpt

Oncoprotein expression is controlled at the level of mRNA translation and is regulated by the eukaryotic translation initiation factor 4F (eIF4F) complex. eIF4A, a component of eIF4F, catalyzes the unwinding of secondary structure in the 5’-untranslated region (5’-UTR) of mRNA to facilitate ribosome scanning and translation initiation. Zotatifin (eFT226) is a selective eIF4A inhibitor that increases the affinity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Eosinophilic Disorders and Syndromes
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34900714
DOI: 10.3389/fonc.2021.766298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven TumorsPMID 34900714Read ↗

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer TherapySemantic proximity Read ↗

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerSemantic proximity Read ↗

Translation Initiation Represents an Acute Myeloid Leukemia Cell Vulnerability That Can Be Co-Targeted With BCL-2 InhibitionSemantic proximity Read ↗

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerSemantic proximity Read ↗

Targeting the eIF4F translation initiation complex for cancer therapySemantic proximity Read ↗

Effective inhibition of MYC-amplified Group 3 medulloblastoma through targeting translation machinery eIF4F complexSemantic proximity Read ↗

Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cellsSemantic proximity Read ↗

RFC4 Drives Temozolomide Resistance in Glioblastoma by Activating STK38-BECN1-Dependent AutophagySemantic proximity Read ↗

Targeting Mnks for Cancer TherapySemantic proximity Read ↗

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axisSemantic proximity Read ↗

Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy.Semantic proximity Read ↗

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.